CancerDrs

Prostate Cancer clinical trials in District of Columbia

8 actively recruiting prostate cancer trials at 1 site across District of Columbia.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in District of Columbia:
  • George Washington University Medical Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in District of Columbia:
  • Sibley Memorial Hospital — Washington D.C., District of Columbia
  • George Washington University Medical Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
  • MedStar Washington Hospital Center — Washington D.C., District of Columbia
  • George Washington University Medical Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in District of Columbia:
  • MedStar Georgetown University Hospital — Washington D.C., District of Columbia
  • MedStar Washington Hospital Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in District of Columbia:
  • Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in District of Columbia:
  • The GW Medical Faculty Associates ( Site 0057) — Washington D.C., District of Columbia
  • Washington DC Veterans Affairs Medical Center ( Site 0056) — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
Phase 4 Recruiting Industry

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred t…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05803941
Sites in District of Columbia:
  • VA Medical Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors

This pilot study will recruit Black/African American prostate cancer survivors into a clinical trial and will randomize each person to 1 of 2 possible treatments - an internet-based treatment for insomnia called Sleep Healthy Using the Int…

Sponsor: Georgetown University
NCT ID: NCT07128927
Sites in District of Columbia:
  • Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12